

Supplementary file 3-3. Event rates of CV mortality according to AF status in patients with HFrEF, HFmrEF, and HFpEF (Continued)

Subgroup	HFrEF (EF<40%)				HFmrEF (EF 40-49%)				HFpEF (EF≥50%)			
	Cases (%)		Hazard Ratios (AF vs. without AF)	P <sub>interaction</sub>	Cases (%)		Hazard Ratios (AF vs. without AF)	P <sub>interaction</sub>	Cases (%)		Hazard Ratios (AF vs. without AF)	P <sub>interaction</sub>
	Without AF	With AF			Without AF	With AF			Without AF	With AF		
<b>Age</b>												
<65 years	98 (10.9)	29 (9.0)		0.930	11 (7.1)	5 (8.2)		0.619	14 (7.3)	4 (3.4)		0.085
≥65 years	291 (21.3)	112 (18.7)			59 (15.9)	40 (13.9)			67 (12.2)	76 (15.4)		
<b>Sex</b>												
Male	238 (17.5)	87 (14.8)		0.413	33 (12.5)	16 (10.7)		0.736	31 (10.5)	31 (13.6)		0.496
Female	151 (16.8)	54 (16.3)			37 (14.1)	29 (14.6)			50 (11.1)	49 (12.7)		
<b>Location</b>												
De novo HF	149 (12.2)	31 (7.6)		0.076	36 (11.0)	16 (9.8)		0.875	44 (9.3)	21 (7.8)		0.225
ADHF	240 (23.1)	110 (21.5)			34 (17.1)	29 (15.8)			37 (13.8)	59 (17.2)		
<b>Hypertension</b>												
No	130 (14.1)	51 (13.1)		0.881	16 (9.7)	15 (12.3)		0.386	17 (7.0)	26 (12.6)		0.107
Yes	259 (19.3)	90 (16.9)			54 (14.9)	30 (13.3)			64 (12.8)	54 (13.3)		
<b>Diabetes Mellitus</b>												
No	193 (15.6)	81 (13.6)		0.502	39 (13.5)	26 (10.6)		0.087	45 (9.5)	61 (14.4)		0.033
Yes	196 (19.2)	60 (18.3)			31 (13.0)	19 (18.4)			36 (13.4)	19 (10.0)		
<b>Renal failure</b>												
No	204 (12.7)	68 (10.0)		0.057	30 (8.7)	31 (11.1)		0.521	48 (8.9)	49 (9.7)		0.115
Yes	185 (28.3)	73 (29.9)			40 (22.0)	14 (20.3)			33 (16.4)	31 (28.2)		
<b>Prior stroke</b>												
No	322 (16.3)	115 (15.2)		0.158	60 (13.1)	38 (13.8)		0.378	63 (9.8)	60 (12.1)		0.536
Yes	67 (23.1)	26 (15.8)			10 (14.3)	7 (9.9)			18 (18.2)	20 (17.1)		

AF, atrial fibrillation; EF, ejection fraction; HFrEF, heart failure with reduced ejection fraction; HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; ADHF, acute decompensated heart failure; NYHA, New York Heart Association; DM, diabetes mellitus; IHD, ischemic heart disease.

## Supplementary file 3-3. Event rates of CV mortality according to AF status in patients with HFrEF, HFmrEF, and HFpEF

Subgroup	HFrEF (EF<40%)				HFmrEF (EF 40-49%)				HFpEF (EF≥50%)			
	Cases (%)		Hazard Ratios (AF vs. without AF)	P <sub>interaction</sub>	Cases (%)		Hazard Ratios (AF vs. without AF)	P <sub>interaction</sub>	Cases (%)		Hazard Ratios (AF vs. without AF)	P <sub>interaction</sub>
	Without AF	With AF			Without AF	With AF			Without AF	With AF		
<b>Beta-blockers</b>												
No	174 (22.9)	66 (23.0)		0.380	27 (17.8)	19 (14.7)		0.649	41 (11.6)	42 (15.6)		0.531
Yes	215 (14.3)	75 (11.8)			43 (11.5)	26 (11.9)			40 (10.2)	38 (11.0)		
<b>ACEI or ARB</b>												
No	122 (30.7)	53 (26.9)		0.883	23 (15.9)	9 (9.7)		0.135	26 (9.6)	37 (14.9)		0.206
Yes	267 (14.3)	88 (12.2)			47 (12.3)	36 (14.1)			55 (11.7)	43 (11.7)		
<b>AA</b>												
No	171 (21.0)	63 (18.6)		0.962	32 (11.2)	15 (10.3)		0.770	52 (12.7)	32 (13.0)		0.261
Yes	218 (15.1)	78 (13.4)			38 (15.7)	30 (14.9)			29 (8.7)	48 (13.0)		

AF, atrial fibrillation; EF, ejection fraction; HFrEF, heart failure with reduced ejection fraction; HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; ADHF, acute decompensated heart failure; NYHA, New York Heart Association; DM, diabetes mellitus; IHD, ischemic heart disease.